Literature DB >> 28028755

Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.

Carmem Patrícia Barbosa1, Lívia Bracht2, Franciele Queiroz Ames1, Francielli Maria de Souza Silva-Comar1, Rafael Prizon Tronco3, Ciomar Aparecida Bersani-Amado4.   

Abstract

Statins are hypocholesterolemic drugs that are prescribed for patients with an increased risk of cardiovascular and cerebrovascular complications. Ezetimibe has an atheroprotective activity through inhibition of the expression of vascular adhesion molecule-I and vascular CD14, a marker of the infiltration of mononuclear leukocytes. Ezetimibe reduces the amount of chemoattractant protein-1 that is available for monocytes and macrophages and alters the activity of nuclear factor κB in leukocytes. The mechanisms of action of statins complement those of ezetimibe. Previous studies have demonstrated that the combination of statins and ezetimibe has beneficial effects, including antiinflammatory activity. The present study evaluated the effects of monotherapy with ezetimibe and simvastatin compared with ezetimibe + simvastatin combined on the evolution of the inflammatory response in a rat model of Complete Freund's Adjuvant-induced arthritis. The animals were treated with 10 mg/kg ezetimibe, 40 mg/kg simvastatin, or 10 mg/kg ezetimibe + 40 mg/kg simvastatin for 1, 7, 14, or 28 days. We analyzed leukocyte rolling behavior, leukocyte adhesion to the endothelium, the number of leukocytes that were recruited to the knee joint cavity, and the concentration of cytokines that are involved in the inflammatory response. The data were analyzed using paired t tests or analysis of variance followed by Bonferroni post hoc test. The treatments reduced leukocyte rolling behavior and leukocyte adhesion. The monotherapies did not change the number of leukocytes that were recruited to the knee joint cavity, whereas the ezetimibe + simvastatin combination significantly reduced this parameter. The treatments reduced the levels of proinflammatory cytokines and increased the levels of the antiinflammatory cytokine IL-10, indicating antiinflammatory properties of these drugs in this experimental model of inflammation.

Entities:  

Keywords:  adjuvant-induced arthritis; cell adhesion; cytokine; ezetimibe; rolling behavior; simvastatin

Mesh:

Substances:

Year:  2017        PMID: 28028755     DOI: 10.1007/s10753-016-0497-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  38 in total

1.  Topical anti-inflammatory effect of hypocholesterolaemic drugs.

Authors:  Lívia Bracht; Silvana Martins Caparroz-Assef; Thiago Ferreira dos Santos Magon; Alessandra Mileni Versuti Ritter; Roberto Kenji Nakamura Cuman; Ciomar Aparecida Bersani-Amado
Journal:  J Pharm Pharmacol       Date:  2011-05-19       Impact factor: 3.765

2.  Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.

Authors:  Scott W Altmann; Harry R Davis; Li-Ji Zhu; Xiaorui Yao; Lizbeth M Hoos; Glen Tetzloff; Sai Prasad N Iyer; Maureen Maguire; Andrei Golovko; Ming Zeng; Luquan Wang; Nicholas Murgolo; Michael P Graziano
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

3.  Statin therapy in Alzheimer's disease.

Authors:  Miia Kivipelto; Alina Solomon; Bengt Winblad
Journal:  Lancet Neurol       Date:  2005-09       Impact factor: 44.182

4.  Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy.

Authors:  Claire Arnaud; François Mach
Journal:  Arthritis Rheum       Date:  2006-02

Review 5.  Arguments for interleukin 1 as a target in chronic arthritis.

Authors:  W B van den Berg
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  Striated muscle safety of ezetimibe/simvastatin (Vytorin).

Authors:  Michael H Davidson; Darbie Maccubbin; Michael Stepanavage; John Strony; Thomas Musliner
Journal:  Am J Cardiol       Date:  2005-11-21       Impact factor: 2.778

7.  Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis.

Authors:  V D Wahane; V L Kumar
Journal:  Pharmacol Res       Date:  2009-12-01       Impact factor: 7.658

8.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Authors:  David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation.

Authors:  Su-Young Park; Jong-Suk Lee; Yu Jin Ko; Ah Ra Kim; Mi Kyoung Choi; Mi-Kyoung Kwak; Han Gon Choi; Chul Soon Yong; Jung-Ae Kim
Journal:  Arch Pharm Res       Date:  2008-02       Impact factor: 4.946

10.  Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes.

Authors:  F Montecucco; F Burger; G Pelli; N K Poku; C Berlier; S Steffens; F Mach
Journal:  Rheumatology (Oxford)       Date:  2009-01-16       Impact factor: 7.580

View more
  6 in total

1.  Mevastatin promotes neuronal survival against Aβ-induced neurotoxicity through AMPK activation.

Authors:  Edy Kornelius; Hsin-Hua Li; Chiung-Huei Peng; Hui-Wen Hsiao; Yi-Sun Yang; Chien-Ning Huang; Chih-Li Lin
Journal:  Metab Brain Dis       Date:  2017-08-24       Impact factor: 3.584

2.  Atorvastatin is associated with reduced cisplatin-induced hearing loss.

Authors:  Katharine A Fernandez; Paul Allen; Maura Campbell; Brandi Page; Thomas Townes; Chuan-Ming Li; Hui Cheng; Jaylon Garrett; Marcia Mulquin; Anna Clements; Deborah Mulford; Candice Ortiz; Carmen Brewer; Judy R Dubno; Shawn Newlands; Nicole C Schmitt; Lisa L Cunningham
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

3.  Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.

Authors:  Xue-Mei Liu; Xiao-Min Zhao; Chao Deng; Yan-Ping Zeng; Chang-Hua Hu
Journal:  Acta Pharmacol Sin       Date:  2019-02-06       Impact factor: 6.150

4.  Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I.

Authors:  Graziela Vieira; Juliana Cavalli; Elaine C D Gonçalves; Tainara R Gonçalves; Larissa R Laurindo; Maíra Cola; Rafael C Dutra
Journal:  Front Pharmacol       Date:  2017-09-04       Impact factor: 5.810

Review 5.  Neuroprotective effects of statins against amyloid β-induced neurotoxicity.

Authors:  Hsin-Hua Li; Chih-Li Lin; Chien-Ning Huang
Journal:  Neural Regen Res       Date:  2018-02       Impact factor: 5.135

Review 6.  Implications on the Therapeutic Potential of Statins via Modulation of Autophagy.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Saeed Aslani; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2021-07-30       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.